PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients

Bachelot T(2012)Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study J Clin Oncol 30 2718-2724

Bourgier C(2011)Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 366 520-529

Cropet C(2005)Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells Cancer Res 65 10992-11000

Ray-Coquard I(2003)PTEN and cancer Methods Mol Biol 222 147-166

Ferrero JM(2005)Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor Endocrinology 146 4609-4618

Freyer G(2006)PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma J Pathol 208 350-355

Badie-Lacourtoisie S(2001)Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance J Biol Chem 276 9817-9824

Eymard JC(2007)Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas Clin Cancer Res 13 6064-6069

Debled M(2010)Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status PLoS One 5 e15031-414

Spaeth D(2007)Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women Clin Cancer Res 13 408-2559

Bachelot T(2012)Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study J Clin Oncol 30 2718-2724

Bourgier C(2011)Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 366 520-529

Cropet C(2005)Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells Cancer Res 65 10992-11000

Ray-Coquard I(2003)PTEN and cancer Methods Mol Biol 222 147-166

Ferrero JM(2005)Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor Endocrinology 146 4609-4618

Freyer G(2006)PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma J Pathol 208 350-355

Badie-Lacourtoisie S(2001)Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance J Biol Chem 276 9817-9824

Eymard JC(2007)Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas Clin Cancer Res 13 6064-6069

Debled M(2010)Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status PLoS One 5 e15031-414

Spaeth D(2007)Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women Clin Cancer Res 13 408-2559